

a1
cont

a mono- or poly-hydroxy acid moisturizing agent in an amount sufficient to exfoliate at least a portion of the patient's skin; and
a pharmaceutically acceptable carrier.

03
a2

7. (Amended) The dermatological agent of claim 1, wherein the moisturizing agent is selected from the group consisting of primrose oil, omega 3 gamma-linolenic acid, flax seed oil, and mixtures thereof.

03

10. (Amended) The dermatological agent of claim 1, further comprising at least one of a cysteine component, magnesium component, manganese component, copper component, or selenium component.

04

12. (Amended) The dermatological agent of claim 1, further comprising at least one of wild yam root extract, wild yam extract, yellow dock extract, bupleurum extract, poria cocos extract, gentian root extract, myrrh gum extract, hawthorn berry extract, marshmallow root extract, rosemary extract, black cohosh extract, soy extract or ginger extract.

04

13. (Amended) The dermatological agent of claim 12, wherein the amount of wild yam root extract, wild yam extract, marshmallow root extract, hawthorn berry extract, and rosemary extract, if present, is from about 0.5 to 8 weight percent each, the amount of yellow dock extract, if present, is from about 1 to 30 weight percent, and the amount of bupleurum extract, poria cocos extract, gentian root and myrrh gum extract, if present, is from about 1 to 20 weight percent each.

05

17. (Amended) The dermatological agent of claim 1, which further comprises at least one immunity boosting component in an amount sufficient to stimulate the patient's immune system response to prevent damage of skin or facilitate the repair of skin.

06

24. (Amended) A dermatological agent for managing a dermatological condition in a patient comprising:

at least one fruit extract in an amount sufficient to neutralize free radicals;
a transition metal component in an amount sufficient to inhibit or reduce
inflammation;
a hydrophobic moisturizing agent in an amount sufficient to facilitate
hydration of the patient's skin;
a hydrophilic moisturizing agent in an amount sufficient to facilitate hydration
of the patient's skin;
a mono- or poly-hydroxy acid moisturizing agent in an amount sufficient to
exfoliate at least a portion of the patient's skin; and
a pharmaceutically acceptable carrier.

A list of currently pending claims is provided in Appendix B for the
Examiner's convenience.

REMARKS

Claims 1-27 are pending in the application for the Examiner's review and consideration. Claims 1 and 24 were amended to delete the recitation in a patient "having skin." Claim 1 was also amended to recite that the composition includes a hydrophobic moisturizing agent, a hydrophilic moisturizing agent, and a mono- or poly-hydroxy moisturizing agent (*See, e.g.*, Specification, page 19-25). Claim 7 was amended to replace the abbreviation "GLA-3" with the full name "omega 3 gamma linolenic acid." Claim 9 was amended to merely recite petrolatum which is the same as red veterinary petrolatum. Claim 10 was amended to correct a typographical omission. Claim 10 was amended to recite that the dermatological composition further includes "one or more of a . . ." (*See, e.g.*, Specification, page 15, lines 26-28). Claims 12 and 13 were amended to recite that each component is an extract (*See, e.g.*, Specification, page 17, line 4 to page 19, line 6). As no new matter has been added, Applicant respectfully submits that all claims are in condition for allowance.

THE OBJECTION

Claims 3, 5-7, 16, 17, and 21 were objected to for the reasons set forth on page 2 of the Office Action. Claims 3, 5-7, 16, and 21 were objected to for reciting an improper